Search results for "Drug Monitoring"

showing 10 items of 119 documents

Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents

2020

PURPOSE Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C/D) expected in a "normal" population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adul…

MaleDrugTopiramatePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentmedia_common.quotation_subjectPopulation030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsparasitic diseasesHumansMedicinePharmacology (medical)ChildeducationAntipsychoticOxcarbazepinemedia_commonPharmacologyeducation.field_of_studyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryAge FactorsArea under the curveAntidepressive AgentsTherapeutic drug monitoringArea Under CurveAnticonvulsantsCentral Nervous System StimulantsFemaleDrug MonitoringbusinessAntipsychotic AgentsHalf-Lifemedicine.drugTherapeutic Drug Monitoring
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P < 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients

2018

Abstract Introduction Many antidepressants cause QT prolongation but the classification of cardiac risk of these drugs varies markedly in different published lists. This retrospective study analyzed the correlation of QTc time with amitriptyline and venlafaxine serum level in elderly psychiatric inpatients. Methods Elderly inpatients aged≥65 years for whom venlafaxine or amitriptyline serum level had been measured were selected retrospectively from a therapeutic drug monitoring database and screened for an electrocardiogram measurement at the time of blood withdrawal. The correlation of amitriptyline or venlafaxine serum levels with QTc time was examined by using Pearson’s correlation analy…

MaleDrugmedicine.medical_specialtyDatabases FactualAmitriptylinemedia_common.quotation_subjectVenlafaxineQT intervalElectrocardiography03 medical and health sciences0302 clinical medicineTherapeutic indexPharmacokineticsmedicineHumansPharmacology (medical)Amitriptyline030212 general & internal medicinePsychiatryAgedRetrospective Studiesmedia_commonAged 80 and overInpatientsmedicine.diagnostic_testbusiness.industryVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineAntidepressive AgentsLong QT SyndromePsychiatry and Mental healthTherapeutic drug monitoringFemalebusiness030217 neurology & neurosurgerymedicine.drugPharmacopsychiatry
researchProduct

Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil

2015

BACKGROUND Aiming to verify that therapeutic drug monitoring has the potential to optimize treatment with acetylcholine esterase inhibitors of patients with Alzheimer dementia, this study investigated whether serum concentrations of donepezil are associated with clinical improvement. METHODS Clinical improvement was measured using the clinical global impression (CGI) scale, and donepezil concentrations were measured in serum by a high-performance liquid chromatographic method with spectrophotometric detection. RESULTS In total, 206 serum samples from 106 patients (49.5% female) were retrospectively available for analysis. Patients included were treated under everyday conditions. Their mean …

MaleDrugmedicine.medical_specialtymedia_common.quotation_subjectGastroenterologyPiperidinesAlzheimer DiseaseInternal medicinemental disordersmedicineHumansDonepezilPharmacology (medical)DonepezilAgedRetrospective Studiesmedia_commonPharmacologyDose-Response Relationship DrugReceiver operating characteristicmedicine.diagnostic_testbusiness.industryRetrospective cohort studyAlzheimer dementiaDose–response relationshipTreatment OutcomeTherapeutic drug monitoringIndansClinical Global ImpressionFemaleCholinesterase InhibitorsDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and C…

2022

Abstract Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. Experimental Design: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic sing…

MaleOncologyCancer Researchmedicine.medical_specialtyNeoplasm ResidualAdjuvant chemotherapyClinical Decision-MakingCirculating Tumor DNAText miningPredictive Value of TestsInternal medicineBiomarkers TumorStage III colorectal cancermedicineAdjuvant therapyHumansTumor growthAgedNeoplasm Stagingbusiness.industryPrognosisMinimal residual diseaseConfidence intervalOncologyCirculating tumor DNAFemaleDrug MonitoringNeoplasm Recurrence LocalColorectal NeoplasmsbusinessClinical Cancer Research
researchProduct

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

2017

Background The vast majority of prostate cancer presents clinically localized to the prostate without evidence of metastasis. Currently, there are several modalities available to treat this particular disease. Despite radical prostatectomy demonstrating a modest prostate cancer specific mortality benefit in the PIVOT trial, several novel modalities have emerged to treat localized prostate cancer in patients that are either not eligible for surgery or that prefer an alternative approach. Methods Athymic nude mice were subcutaneously inoculated with prostate cancer cells. The mice were divided into four cohorts, one cohort untreated, two cohorts received docetaxel (10 mg/kg) either subcutaneo…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMice NudeAntineoplastic AgentsDocetaxel02 engineering and technologyMetastasisMice03 medical and health sciencesProstate cancerDrug Delivery Systems0302 clinical medicineProstateIn vivoInternal medicinemedicineAnimalsMinimally Invasive Surgical ProceduresProstatectomybusiness.industryProstatectomyProstatic NeoplasmsProstate-Specific Antigen021001 nanoscience & nanotechnologymedicine.diseaseTumor BurdenSurgeryTreatment Outcomemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisCohortMagnetsImmunohistochemistryTaxoidsDrug Monitoring0210 nano-technologybusinessmedicine.drugThe Prostate
researchProduct

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.

2014

Abstract Abstract Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthr…

MalePalliative careReceptors Opioid muAdverse effectSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsReceptorsDrug Dosage CalculationsProspective StudiesAdverse effects; Cancer pain; Palliative care; TapentadolCancer painPain MeasurementAnalgesicsMorphineMedicine (all)General MedicineMiddle AgedTapentadolAnalgesics OpioidTapentadolTreatment OutcomeItalyTolerabilityAnesthesiaPalliative careFemaleDrugDrug Monitoringmedicine.drugCohort studyAdverse effects; Cancer pain; Palliative care; Tapentadol; Aged; Analgesics Opioid; Cohort Studies; Dose-Response Relationship Drug; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Italy; Karnofsky Performance Status; Male; Middle Aged; Morphine; Neoplasms; Pain Management; Pain Measurement; Phenols; Prospective Studies; Receptors Opioid mu; Treatment Outcome; Pain; Medicine (all)PainOpioidDose-Response RelationshipPhenolsmedicineHumansPain ManagementKarnofsky Performance StatusAdverse effectAgedDose-Response Relationship DrugAdverse effectsbusiness.industryCancermedicine.diseaseOpioidmubusinessCancer pain
researchProduct

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in di…

2013

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S vers…

MaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologySeverity of Illness IndexAtorvastatinLongitudinal StudiesRosuvastatin CalciumAged 80 and overeducation.field_of_studySulfonamidesAnticholesteremic AgentsMiddle AgedRosuvastatin CalciumDrug CombinationsCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleDrug MonitoringCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyStatinmedicine.drug_classPopulationHypercholesterolemiaUrologyDiabetes ComplicationsEzetimibeDouble-Blind MethodInternal MedicinemedicineHumansRosuvastatinPyrrolescardiovascular diseaseseducationAgedbusiness.industrynutritional and metabolic diseasesCholesterol LDLFluorobenzenesPyrimidinesSimvastatinHeptanoic AcidsAzetidinesEzetimibe/simvastatinbusinessDiabetic AngiopathiesDiabetesvascular disease research
researchProduct

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST tria…

2010

Introduction: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ)12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients…

MaleSystolic hypertensionOffice VisitsPharmacologySeverity of Illness Indexlaw.inventionHydrochlorothiazideRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerPharmacology (medical)DiureticsImidazolesGeneral MedicineBlood Pressure Monitoring AmbulatoryAntihypertensive AgentLosartanHydrochlorothiazideTreatment OutcomeAcrylatesHypertensionCardiologyDrug Therapy CombinationFemaleDrug MonitoringHumanmedicine.drugmedicine.medical_specialtyAmbulatory blood pressureSystoleLosartan/hydrochlorothiazideThiopheneselderly patientselderlyLosartanStatistics NonparametricDouble-Blind MethodThiopheneInternal medicinemedicineDiureticHumansImidazoleAntihypertensive AgentsAgedAnalysis of Variancebusiness.industryeprosartanEprosartanmedicine.diseaseambulatory blood pressure monitoringAcrylateBlood pressureOffice VisitbusinessAngiotensin II Type 1 Receptor BlockersAdvances in therapy
researchProduct

Hyperalgesia and opioid switching

2005

Opioids, intended to abolish pain, can unexpectedly produce hyperalgesia, particularly during rapid opioid escalation. Opioid switching could be a therapeutic option in a condition of opioid-induced tolerance or hyperalgesia, but conversion ratios between opioids are difficult to apply in this context and require strict surveillance and expertise. This situation is challenging, because the rapid escalation of opioid doses, possibly due to the development of opioid-induced tolerance, can cause hyperalgesia. To avoid this adverse effect, clinicians need to refine their assessment of pain treatment and consider opioid switching. The authors present a case report in which switching from fentan…

MaleTime FactorsPainContext (language use)Drug Administration ScheduleFentanyl03 medical and health sciences0302 clinical medicine030502 gerontologymedicineHumansAdverse effectPain Measurementbusiness.industryPatient SelectionPalliative CareSarcomaDrug ToleranceGeneral MedicineMiddle AgedThoracic NeoplasmsAnalgesics OpioidFentanylTherapeutic EquivalencyOpioidHyperalgesia030220 oncology & carcinogenesisAnesthesiaHyperalgesiaDrug Monitoringmedicine.symptom0305 other medical scienceCancer painbusinessMethadonemedicine.drugMethadoneAmerican Journal of Hospice and Palliative Medicine®
researchProduct